Safety of COVID-19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study.
作者信息
De Luca Joseph F, Awad Andrew, Vogrin Sara, Douglas Abby P, Lutjen Antje, Gordon Sally F, Crawford Nigel W, Barnes Sara, Trubiano Jason A
机构信息
Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Vic., Australia.
Department of Medicine, University of Melbourne, Melbourne, Vic., Australia.
出版信息
Allergy. 2023 Jan;78(1):293-296. doi: 10.1111/all.15467. Epub 2022 Aug 9.
Abstract
摘要
相似文献
1
Safety of COVID-19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study.既往剂量出现速发型不良反应的患者中新冠病毒疫苗激发试验的安全性：一项多中心队列研究
Allergy. 2023 Jan;78(1):293-296. doi: 10.1111/all.15467. Epub 2022 Aug 9.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.75 岁及以上成年人接种 BNT162b2 新冠疫苗后的安全性监测。
J Korean Med Sci. 2021 Nov 22;36(45):e318. doi: 10.3346/jkms.2021.36.e318.
4
Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.高过敏风险成年人接种辉瑞-BioNTech COVID-19 疫苗后的过敏反应发生率。
JAMA Netw Open. 2021 Aug 2;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255.
5
Immediate reactions after mRNA SARS-CoV-2 vaccination.新型冠状病毒mRNA疫苗接种后的即时反应。
CMAJ. 2021 Dec 6;193(48):E1842. doi: 10.1503/cmaj.211581. Epub 2021 Nov 12.
6
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
7
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
8
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.非酒精性脂肪性肝病患者 COVID-19 疫苗接种的安全性和免疫原性（CHESS2101）：一项多中心研究。
J Hepatol. 2021 Aug;75(2):439-441. doi: 10.1016/j.jhep.2021.04.026. Epub 2021 Apr 24.
9
Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.川崎病病史患者对 COVID-19 感染和信使 RNA 疫苗接种的耐受性。
JAMA Netw Open. 2022 Aug 1;5(8):e2226236. doi: 10.1001/jamanetworkopen.2022.26236.
10
COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.COVID-19 mRNA 疫苗在短期内通常是安全的：一项疫苗监测真实世界研究称。
Front Immunol. 2021 May 21;12:669010. doi: 10.3389/fimmu.2021.669010. eCollection 2021.
引用本文的文献
1
Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.澳大利亚在 COVID-19 大流行期间的疫苗安全：前线经验教训。
Front Public Health. 2022 Nov 4;10:1053637. doi: 10.3389/fpubh.2022.1053637. eCollection 2022.
Zotero 插件